Spero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company — a stock, not an exchange-traded fund — focused on treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases. Unlike heavily covered large caps, SPRO has a thin analyst bench, so the central target here rests on just two individually attributable, current price targets.
HC Wainwright analyst Raghuram Selvaraju raised the firm's target to $6 from $5 on September 14, 2026, reiterating a Buy rating and citing the future market potential of SP001. Separately, Evercore ISI analyst Gavin Clark-Gartner maintained a Hold rating with a $4 target. The arithmetic mean of these two targets is $5, with a range of $4 to $6.
The gap between the two targets captures the disagreement in the Street. The bullish case assumes the oral carbapenem franchise and milestone economics under the GSK collaboration unlock substantial value. The more cautious view — echoed by additional Hold ratings from firms such as TD Cowen — reflects uncertainty over a pipeline with limited late-stage breadth and a company still generating net losses. No analyst consensus figure published by a reputable source independently reports this exact $5 mean, so it should be read as a calculated midpoint, not an official Street consensus.
With SPRO changing hands around $1.14, the $5 target implies a required gain of roughly 339%. By any standard, that is a very large move, not a modest or incremental one. It would demand a fundamental re-rating of a company whose market capitalization currently sits in the tens of millions of dollars.
The path to such a re-rating would have to run through execution, not sentiment alone. Spero's flagship asset, tebipenem HBr — approved in the U.S. as Utebzi, the first oral carbapenem for complicated urinary tract infections (cUTIs) — is being commercialized through a partnership with GSK. Milestone payments and eventual royalties represent the clearest source of future revenue, but the company's reported revenue has been declining and financial forecasts point to a sharp drop in recognized revenue in 2026 as collaboration economics shift.
The strongest pillar is the Utebzi approval. An oral carbapenem addresses a genuine clinical need in cUTIs, where resistance to existing oral antibiotics is rising, and the GSK partnership removes much of the commercial execution burden from a small biotech. Additional candidates, including SP001 and SPR720 for nontuberculous mycobacterial (NTM) pulmonary disease, broaden the longer-term optionality that a $6 target implicitly prices in.
Spero also maintains a clean balance sheet with no meaningful debt, which limits near-term dilution risk and gives management a runway to advance programs. Any positive data readout, milestone payment, or upward analyst revision could compress the valuation gap and refocus attention on the bull thesis.
The obstacles are substantial. Revenue has contracted sharply, and the company continues to report net losses; consensus estimates project negative EPS (earnings per share) in the near term. A clinical-stage pipeline concentrated in a few programs means a single setback can disproportionately affect the valuation.
The stock's thin coverage and wide target range also mean there is little institutional consensus to anchor a re-rating, and any milestone delays, disappointing launch uptake, or unfavorable collaboration economics could pressure the share price further. With a beta near 1.5, SPRO is materially more volatile than the broader market.
SPRO has traded in a wide band, with a 52-week low near $0.51 and a 52-week high around $3.22. The current price sits in the lower portion of that range. The $1 level is a natural psychological support zone, while the prior highs above $3 represent the first meaningful resistance before any run toward $4 or $5. A sustained move toward the target would require first reclaiming the multi-dollar territory the stock briefly occupied and holding above it.
Analyst price targets typically reflect a research horizon of roughly 12 months, though the exact horizon can differ between firms and should not be assumed. The most important catalysts are regulatory and commercial: the progress of the GSK-led Utebzi launch, milestone and royalty recognition, data updates for SP001 and SPR720, and any partnership developments. Quarterly earnings, guidance, and analyst revisions will signal whether the bull thesis is intact.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Rather than relying on a single metric, the system scans for shifting trends and momentum patterns that human review can miss. Traders can use these signals to discover new opportunities, monitor existing positions, and spot changing trends more efficiently. For those watching a volatile, thinly covered name like SPRO, automated signal monitoring can add a useful layer of perspective to fundamental research.
Can Spero Therapeutics (SPRO) stock reach $5? The $5 central target — the mean of the two verified analyst targets of $4 and $6 — implies a roughly 339% advance from near $1.14, a very large move that would require the Utebzi/GSK partnership and the broader pipeline to translate into durable, growing value. The bull case rests on a genuine medical innovation and a strong commercial partner; the bear case rests on shrinking revenue, persistent losses, and concentrated pipeline risk. With only two attributable targets spanning a wide $4-to-$6 range, investors should treat any single figure cautiously and focus on launch execution, milestone recognition, and clinical data as the variables most likely to decide the outcome.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, SPRO has been loosely correlated with CCXI. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRO jumps, then CCXI could also see price increases.
| Ticker / NAME | Correlation To SPRO | 1D Price Change % | ||
|---|---|---|---|---|
| SPRO | 100% | -3.60% | ||
| CCXI - SPRO | 48% Loosely correlated | -0.10% | ||
| ASBP - SPRO | 42% Loosely correlated | -6.74% | ||
| VYGR - SPRO | 35% Loosely correlated | +0.57% | ||
| JAGX - SPRO | 34% Loosely correlated | +16.18% | ||
| VKTX - SPRO | 32% Poorly correlated | -0.78% | ||
More | ||||